ITA4551
ITA4551
ITA4551
from
$526.00
Price in reward points: 526
- Catalog: ITA4551
- Gene/Protein: MRPL41
- Product Description: Immunotag™ MRPL41 Antibody
Available Options
-
Description
Immunotag™ MRPL41 Antibody
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein MRPL41 Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500~1:1000 IHC: 1:50~1:200, IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide Specificity MRPL41 Antibody detects endogenous levels of total MRPL41 Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name MRPL41 Accession No. Q8IXM3 Alternate Names 39S ribosomal protein L27 homolog; 39S ribosomal protein L41; 39S ribosomal protein L41 mitochondrial; Bcl-2-interacting mitochondrial ribosomal protein L41; BMRP; Cell proliferation-inducing gene 3 protein; L41mt; mitochondrial; Mitochondrial ribosomal protein L41; MRP L27; MRP-L27 homolog; MRP-L41; MRPL27; mRpL41; PIG3; Proliferation inducing gene 3; RM41_HUMAN; RPML27; Description Component of the mitochondrial ribosome large subunit (PubMed:25278503, PubMed:25838379). Also involved in apoptosis and cell cycle (PubMed:16024796, PubMed:16256947). Enhances p53/TP53 stability, thereby contributing to p53/TP53-induced apoptosis in response to growth-inhibitory condition. Enhances p53/TP53 translocation to the mitochondria. Has the ability to arrest the cell cycle at the G1 phase, possibly by stabilizing the CDKN1A and CDKN1B (p27Kip1) proteins (PubMed:16024796). Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 21 KD Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | MRPL41 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500~1:1000 IHC: 1:50~1:200, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide |
| Specificity | MRPL41 Antibody detects endogenous levels of total MRPL41 |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | MRPL41 |
| Accession No. | Q8IXM3 |
| Alternate Names | 39S ribosomal protein L27 homolog; 39S ribosomal protein L41; 39S ribosomal protein L41 mitochondrial; Bcl-2-interacting mitochondrial ribosomal protein L41; BMRP; Cell proliferation-inducing gene 3 protein; L41mt; mitochondrial; Mitochondrial ribosomal protein L41; MRP L27; MRP-L27 homolog; MRP-L41; MRPL27; mRpL41; PIG3; Proliferation inducing gene 3; RM41_HUMAN; RPML27; |
| Description | Component of the mitochondrial ribosome large subunit (PubMed:25278503, PubMed:25838379). Also involved in apoptosis and cell cycle (PubMed:16024796, PubMed:16256947). Enhances p53/TP53 stability, thereby contributing to p53/TP53-induced apoptosis in response to growth-inhibitory condition. Enhances p53/TP53 translocation to the mitochondria. Has the ability to arrest the cell cycle at the G1 phase, possibly by stabilizing the CDKN1A and CDKN1B (p27Kip1) proteins (PubMed:16024796). |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 21 KD |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |